Perampanel + Standard of Care
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioma, Malignant
Conditions
Glioma, Malignant, Surgery, Seizures
Trial Timeline
Nov 5, 2020 → May 16, 2023
NCT ID
NCT04497142About Perampanel + Standard of Care
Perampanel + Standard of Care is a phase 1/2 stage product being developed by Eisai for Glioma, Malignant. The current trial status is completed. This product is registered under clinical trial identifier NCT04497142. Target conditions include Glioma, Malignant, Surgery, Seizures.
What happened to similar drugs?
0 of 3 similar drugs in Glioma, Malignant were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04497142 | Phase 1/2 | Completed |
Competing Products
20 competing products in Glioma, Malignant
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Temozolomide | Novocure | Phase 1 | 15 |
| Enzastaurin (LY317615) + Carboplatin | Eli Lilly | Phase 1 | 29 |
| LY2157299 + Lomustine | Eli Lilly | Phase 1 | 29 |
| DS-1001b | Daiichi Sankyo | Phase 2 | 39 |
| DS-1001b | Daiichi Sankyo | Phase 1 | 33 |
| Temozolomide and Bevacizumab | Eisai | Phase 2 | 31 |
| Temozolomide | Eisai | Phase 2 | 31 |
| Gliadel Wafer + Temozolomide | Eisai | Phase 2 | 31 |
| Palonosetron (PALO) | Eisai | Phase 2 | 35 |
| Gliadel/Avastin/CPT-11 | Eisai | Phase 2 | 27 |
| Lenvatinib + Bevacizumab | Eisai | Phase 2 | 35 |
| Granisetron + Ondansetron | Kyowa Kirin | Phase 2 | 27 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 42 |
| Enzastaurin | Eli Lilly | Phase 2 | 35 |
| Pembrolizumab + Pemetrexed + Abemaciclib | Eli Lilly | Phase 1 | 21 |
| LY2157299 + Radiation + Temozolomide | Eli Lilly | Phase 1/2 | 32 |
| Abemaciclib + Temozolomide | Eli Lilly | Phase 2 | 39 |
| DSP-0390 | Sumitomo Pharma | Phase 1 | 36 |
| DSP-0390 | Sumitomo Pharma | Phase 1 | 33 |
| Apatinib | Jiangsu Hengrui Medicine | Phase 2 | 31 |